Bionomics Limited

ABN 53 075 582 740

ASX ANNOUNCEMENT
18 September 2012

Bionomics Appoints Graeme Kaufman Non-Executive Director

18 September 2012 Adelaide: Bionomics Limited (ASX: BNO, ADR: BMICY) has appointed Graeme Kaufman as non-executive director.

Graeme Kaufman is a 45-year veteran of the biotechnology sector in Australia, spending the majority of that time at renowned worldwide pharmaceutical company CSL. At CSL he progressed through a number of roles including Production Director, CFO and General Manager of Biosciences. He was also one of the driving forces behind the privatisation and ASX listing of CSL.

Currently Graeme is Executive Vice-President of Corporate Finance with Mesoblast Ltd. He also previously sat on the boards of Circadian Technologies Ltd, Amrad Corporation and Strategic Life Sciences Ltd before joining Lodge Partners in a corporate finance position.

“Graeme is one of the most respected individuals in the Australian biotech sector, bringing with him a wealth of experience from a diversity of roles,” said Bionomics’ Chairman, Chris Fullerton

“He is a firm believer in the direction Bionomics is taking and we know the company will benefit from Graeme’s depth of life sciences commercial experience and his networks here and abroad.”

Graeme commented “I’ve been impressed by Bionomics’ focused strategic approach to clinical development, building on an experienced team to support both its own substantial product pipeline and its partnered programs”.

Graeme is a chemistry and biochemistry graduate of Melbourne University where he also completed his MBA.

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 /
0418 160 425
drathjen@bionomics.com.au

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group
Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis.

BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. BNC105 offers blockbuster potential if successfully developed. A clinical program is also underway for the treatment of anxiety disorders and depression based on BNC210, a novel compound which stimulates neurite outgrowth. BNC210 is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system. These platforms underpin Bionomics' established business strategy and Bionomics is committed to securing partners for its key compounds.

For more information about Bionomics, visit www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to the clinical evaluation of either BNC105 or BNC210, our partnership Ironwood Pharmaceuticals, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.